Efficacy and safety of the proposed bevacizumab biosimilar <scp>BAT1706</scp> compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase <scp>III</scp> study
Cancer medicine